DataMeds AI Licenses Exclusive US Rights to Reboot Health AI's GLP — 1 Management Platform

DataMeds AI entered an exclusive agreement licensing U.S. direct-to-consumer rights to Reboot Health AI's care management platform for GLP-1 patients. The platform will be integrated into the Health Lives Here app through monthly subscriptions, with revenue shared between the companies. The license covers intellectual property comprising six patents and six pending patent applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)